Replies to post #2030 on Adhera Therapeutics Inc (ATRX)

[Threeflight]

No, I think you nailed it.

[Bawz2wawz]

Largest volume since last April.

[surf1944]

Bought back into MRNA, starting to see biotech stocks bouncing on stock secondary news, not as worried about MRNA offering news if/when it comes.

Avg Vol (3 month)3: 199,703
Avg Vol (10 day)3: 226,250
Shares Outstanding5: 25.39M
Float: 23.80M
% Held by Insiders6: 31.46%
% Held by Institutions6: 3.90%
Shares Short (as of Dec 31, 2010)3: 985.87K
Short Ratio (as of Dec 31, 2010)3: 3.50
Short % of Float (as of Dec 31, 2010)3: 8.10%
Shares Short (prior month)3: 994.48K

[surf1944]

this is part of the bottoming process for MRNA, getting this out of the way & the insider selling completed, will help form a base in the coming weeks....

Marina Biotech Announces Proposed Public Offering of Common Stock and Warrants

Marina Biotech, Inc. On Wednesday February 9, 2011, 4:01 pm EST

BOTHELL, WA--(Marketwire - 02/09/11) - Marina Biotech, Inc. (NASDAQ:MRNA - News), a leading RNAi-based drug discovery and development company, today announced that it intends to offer and sell units consisting of shares of its common stock and warrants to purchase common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Roth Capital Partners, LLC is acting as the sole manager for the offering.

Marina Biotech intends to use the proceeds from this offering for general corporate purposes (including working capital and operational purposes) and toward the clinical development of CEQ 508, which is currently in a Phase 1b/2a clinical trial for the treatment of Familial Adenomatous Polyposis (FAP).

The units are being offered by Marina Biotech pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on September 30, 2010. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Roth Capital Partners, LLC Syndicate Department, 24 Corporate Plaza, Newport Beach, CA 92660, at 800-678-9147 and [e-mail]. Before you invest, you should read the preliminary prospectus supplement and the accompanying prospectus in that registration statement and other documents Marina Biotech has filed or will file with the SEC for more complete information about Marina Biotech and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.